A Phase 3 interventional study of Sumatriptan and Naproxen Sodium and Placebo in Migraine Disorders, sponsored by GlaxoSmithKline. Completed at 79 sites in United States. Open to participants aged 12 Years to 17 Years. Per ClinicalTrials.gov, last updated 2017-01-18.
Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 42 studies testing sumatriptan in Migraine Disorders — none open to participants now, none under way, none of them phase 3. Sumatriptan · Migraine Disorders.
Among the 42 studies testing sumatriptan in Migraine Disorders, this one is the 6th largest by enrollment, is one of 4 that started in 2008, is one of 18 in phase 3, and was the 15th registered.
1,660 studies on the registry are indexed under Migraine Disorders; 341 are open to participants now.
Browse Migraine Disorders studies →None of the 42 studies testing sumatriptan in Migraine Disorders is open now. The open studies under Migraine Disorders, anywhere →
Sumatriptan: first FDA approval 1992 (IMITREX STATDOSE (AUTOINJECTOR)). What it is approved for, and how studies give it, is on its page →
Of the 217 Migraine Disorders studies recruiting now, 66 (30%) set no upper age limit and 136 (63%) stop at 75 or younger; 44 take children under 18; 37 take healthy volunteers.
This study: 12 Years to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
42 studies; the count open now beside each. This study's row is marked.
First in 1995; this study’s year is marked. 4 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 589 is above the median of 80 across 1,271 interventional studies indexed under Migraine Disorders.
Median enrollment 74 across the 42 interventional studies. Of the 40 that completed or were terminated, 20 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
27 of 42 have an industry lead sponsor. The 10 most frequent:
GlaxoSmithKline is the lead sponsor of 3,652 studies on the registry; 117 are open to participants now.
Of its 268 completed or terminated interventional studies of FDA-regulated products, 242 (90%) have results posted.
28 studies in Migraine Disorders by GlaxoSmithKline: none open now, none under way, none of them phase 3. Of 28 finished, 11 (39%) have results posted.
Among the 28 studies in Migraine Disorders by GlaxoSmithKline, this one is the 5th largest by enrollment of the 19 interventional ones that give a count, is one of 5 that started in 2008, is one of 13 in phase 3, and was the 17th registered.
GlaxoSmithKline’s Migraine Disorders studies by the year they started, since 2001.
None of the studies under way reaches primary completion within a year.
Among the 42 studies testing sumatriptan in Migraine Disorders, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among GlaxoSmithKline’s 28 in Migraine Disorders:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study was designed to determine how well the combination medication, sumatriptan and naproxen sodium, treats migraine headache in adolescents 12-17 years old
The purpose of this study is to determine whether the combination product, sumatriptan and naproxen sodium, is effective compared to placebo in the treatment of acute migraine in adolescent subjects 12-17 years old. Subjects will treat two migraine attacks over a \~25 week period.
Inclusion Criteria: Subjects eligible for enrollment in the study must meet all of the following criteria:
Male or female subjects. Female subjects are eligible for participation in the study if they are:
Subject is willing and able to provide Informed Assent prior to entry into the study (if required).
-
Exclusion Criteria:
Subjects meeting any of the following criteria must not be enrolled in the study:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Sumatriptan succinate and naproxen sodium combination 10mg/60mg
Drug: Sumatriptan and Naproxen Sodium
Sumatriptan succinate and naproxen sodium combination 30mg/180mg
Drug: Sumatriptan and Naproxen Sodium
Sumatriptan succinate and naproxen sodium combination 85mg/500mg
Drug: Sumatriptan and Naproxen Sodium
Placebo to match
Drug: Placebo
Drug pages: SumatriptanStudies of SumatriptanSumatriptan pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · NaproxenStudies of NaproxenNaproxen pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
Sumatriptan succinate and naproxen sodium
Placebo to match
Number of Participants Who Were Pain Free at 2 Hours Post-dose
Participants were evaluated (self-assessment) for pain intensity by using a 4-point rating scale: 0=none, 1=mild, 2=moderate, and 3=severe. Participants with pain-free response were considered as those who had a reduction in migraine headache pain from moderate (score=2) or severe (score=3) at baseline to none (score=0) post-treatment, without the use of rescue medication (additional medication taken by participants for the treatment of migraine pain or associated symptoms) prior to or at 2 hours post-dose.
Time frame: 2 hours after single dose of double-blind treatment (Randomization through Week 13)
Number of Participants Sustained Pain-free From 2-24 Hours
Participants with sustained pain-freedom were defined as those with pain-freedom at 2 hours post-dose that was maintained up to 24 hours post-treatment without the use of rescue medication.
Time frame: 2 to 24 hours after single dose of double-blind treatment (Randomization through Week 13)
Number of Participants Photophobia-free at 2 Hours Post-dose
The number of participants who did not have photophobia (sensitivity to light) at 2 hours post dose was analyzed.
Time frame: 2 hours after single dose of double-blind treatment (Randomization through Week 13)
Number of Participants Phonophobia-free at 2 Hours Post-dose
The number of participants who did not have phonophobia (sensitivity to sound) at 2 hours post dose was analzyed.
Time frame: 2 hours after single dose of double-blind treatment (Randomization through Week 13)
Number of Participants Pain-free at 1 Hour Post-dose
Participants with a pain-free response at 1 hour post-dose were considered as those who had a reduction in migraine headache pain from moderate (a score of 2) or severe (a score of 3) at baseline to none (a score of 0) post-treatment, without the use of rescue medication prior to or at 1 hour post dose.
Time frame: 1 hour after single dose of double-blind treatment (Randomization through Week 13)
Number of Participants Sustained Photophobia-free From 2-24 Hours
Participants with sustained freedom from photophobia were those with an absence of photophobia (sensitivity to light) from 2 to 24 hours post-dose without the use of rescue medication.
Time frame: 2 to 24 hours after single dose of double-blind treatment (Randomization through Week 13)
Number of Participants Sustained Phonophobia-free From 2-24 Hours
Participants with sustained freedom from phonophobia were those with an absence of phonophobia (sensitivity to sound) from 2 to 24 hours post-dose without the use of rescue medication.
Time frame: 2 to 24 hours after single dose of double-blind treatment (Randomization through Week 13)
Number of Participants Sustained Nausea-free From 2-24 Hours
Participants with sustained freedom from nausea were those with an absence of nausea from 2 to 24 hours post-dose without the use of rescue medication.
Time frame: 2 to 24 hours after single dose of double-blind treatment (Randomization through Week 13)
Number of Participants Who Used Rescue Medication From 2 to 24 Hours Post Dose
Rescue medication was defined as an additional medication taken by participants for the treatment of migraine pain or associated symptoms within 24 hours of dosing with investigational product. Permitted rescue medications included oral naproxen sodium (maximum 15 mg/kg), oral over-the-counter pain reliever, and anti-emetics. This outcome measure included only participants who rescued from 2 to 24 hours post-dose, inclusive.
Time frame: 2 to 24 hours after single dose of double-blind treatment (Randomization through Week 13)
Number of Participants Who Used Their First Dose of Rescue Medication Through the Indicated Time Points
Rescue medication was defined as an additional medication taken by participants for the treatment of migraine pain or associated symptoms within 24 hours of dosing with double-blind treatment. In addition to participants who rescued from 2 to 24 hours post-dose, inclusive, this outcome measure also included nine protocol violators who rescued \< 2 hours post-treatment.
Time frame: Dosing to 24 hours after single dose of double-blind treatment (Randomization through Week 13)
Number of Participants Nausea-free at 2 Hours Post-dose
The number of participants who did not have nausea at 2 hours post dose was analzyed.
Time frame: 2 hours after single dose of double-blind treatment (Randomization through Week 13)
Mean Age of Participants at Baseline Categorized by Age Group
The mean age of participants at baseline was calculated for all participants in the 12 to 14 year and 15 to 17 year age groups.
Time frame: Baseline
Number of Participants Randomized to Double-blind Treatment in the Indicated Age Categories at Baseline
The number of participants receiving double-blind treatment were reported according to age.
Time frame: Baseline
Number of Female and Male Participants Categorized by Age Group
The gender of participants at baseline was reported for all participants in the 12 to 14 year and 15 to 17 year age groups.
Time frame: Baseline
Number of Participants of the Indicated Race Categorized by Age Group
The race of participants at baseline was reported for all participants in the 12 to 14 year and 15 to 17 year age groups.
Time frame: Baseline
Mean Weight of Participants at Baseline Categorized by Age Group
The mean weight of participants at baseline was calculated for all participants in the 12 to 14 year and 15 to 17 year age groups.
Time frame: Baseline
Mean Body Mass Index of Participants at Baseline Categorized by Age Group
The mean body mass index of participants at baseline was calculated for all participants in the 12 to 14 year and 15 to 17 year age groups. Body mass index is calculated as: weight (kilograms \[kg\]) divided by height (meters \[m\]\^2).
Time frame: Baseline
| Milestone | 12 to 14 Years Age Group: Single-blind Phase | 15 to 17 Years Age Group: Single-blind Phase | Placebo | Sumatriptan 10 mg/ Naproxen 60 mg | Sumatriptan 30 mg/ Naproxen 180 mg | Sumatriptan 85 mg/ Naproxen 500 mg |
|---|---|---|---|---|---|---|
| Started | 408 | 457 | 0 | 0 | 0 | 0 |
| Completed | 268 | 321 | 0 | 0 | 0 | 0 |
| Not completed | 140 | 136 | 0 | 0 | 0 | 0 |
| Withdrew: Did not meet continuation criteria | 79 | 74 | 0 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 36 | 31 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 19 | 18 | 0 | 0 | 0 | 0 |
| Withdrew: Protocol violation | 4 | 5 | 0 | 0 | 0 | 0 |
| Withdrew: Physician decision | 2 | 6 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 0 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Other | 0 | 1 | 0 | 0 | 0 | 0 |
| Milestone | 12 to 14 Years Age Group: Single-blind Phase | 15 to 17 Years Age Group: Single-blind Phase | Placebo | Sumatriptan 10 mg/ Naproxen 60 mg | Sumatriptan 30 mg/ Naproxen 180 mg | Sumatriptan 85 mg/ Naproxen 500 mg |
|---|---|---|---|---|---|---|
| Started | 0 | 0 | 176 | 119 | 117 | 177 |
| Completed | 0 | 0 | 145 | 96 | 97 | 152 |
| Not completed | 0 | 0 | 31 | 23 | 20 | 25 |
| Withdrew: No opportunity to treat migraine | 0 | 0 | 20 | 10 | 13 | 14 |
| Withdrew: Lost to follow-up | 0 | 0 | 8 | 4 | 4 | 4 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 6 | 0 | 2 |
| Withdrew: Protocol violation | 0 | 0 | 3 | 0 | 0 | 3 |
| Withdrew: Physician decision | 0 | 0 | 0 | 3 | 1 | 1 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 1 | 1 |
| Withdrew: Lack of efficacy | 0 | 0 | 0 | 0 | 1 | 0 |
Participants were evaluated (self-assessment) for pain intensity by using a 4-point rating scale: 0=none, 1=mild, 2=moderate, and 3=severe. Participants with pain-free response were considered as those who had a reduction in migraine headache pain from moderate (score=2) or severe (score=3) at baseline to none (score=0) post-treatment, without the use of rescue medication (additional medication taken by participants for the treatment of migraine pain or associated symptoms) prior to or at 2 hours post-dose.
| participants | Placebo | Sumatriptan 10 mg/ Naproxen 60 mg | Sumatriptan 30 mg/ Naproxen 180 mg | Sumatriptan 85 mg/ Naproxen 500 mg |
|---|---|---|---|---|
| Total Population, n=142, 96, 97, 150 | 14 | 28 | 26 | 36 |
| 12-14 years, n=70, 43, 46, 65 | 10 | 18 | 13 | 17 |
| 15-17 years, n=72, 53, 51, 85 | 4 | 10 | 13 | 19 |
Participants with sustained pain-freedom were defined as those with pain-freedom at 2 hours post-dose that was maintained up to 24 hours post-treatment without the use of rescue medication.
| participants | Placebo | Sumatriptan 10 mg/ Naproxen 60 mg | Sumatriptan 30 mg/ Naproxen 180 mg | Sumatriptan 85 mg/ Naproxen 500 mg |
|---|---|---|---|---|
| Total Population, n=142, 96, 97, 150 | 13 | 23 | 24 | 35 |
| 12-14 years, n=70, 43, 46, 65 | 10 | 14 | 12 | 17 |
| 15-17 years, n=72, 53, 51, 85 | 3 | 9 | 12 | 18 |
The number of participants who did not have photophobia (sensitivity to light) at 2 hours post dose was analyzed.
| participants | Placebo | Sumatriptan 10 mg/ Naproxen 60 mg | Sumatriptan 30 mg/ Naproxen 180 mg | Sumatriptan 85 mg/ Naproxen 500 mg |
|---|---|---|---|---|
| Total Population, n=144, 96, 96, 151 | 59 | 57 | 47 | 89 |
| 12-14 years, n=71, 43, 46, 65 | 33 | 29 | 24 | 41 |
| 15-17 years, n=73, 53, 50, 86 | 26 | 28 | 23 | 48 |
The number of participants who did not have phonophobia (sensitivity to sound) at 2 hours post dose was analzyed.
| participants | Placebo | Sumatriptan 10 mg/ Naproxen 60 mg | Sumatriptan 30 mg/ Naproxen 180 mg | Sumatriptan 85 mg/ Naproxen 500 mg |
|---|---|---|---|---|
| Total Population, n=144, 96, 96, 151 | 60 | 59 | 55 | 90 |
| 12-14 years, n=71, 43, 46, 65 | 34 | 32 | 33 | 41 |
| 15-17 years, n=73, 53, 50, 86 | 26 | 47 | 22 | 49 |
Participants with a pain-free response at 1 hour post-dose were considered as those who had a reduction in migraine headache pain from moderate (a score of 2) or severe (a score of 3) at baseline to none (a score of 0) post-treatment, without the use of rescue medication prior to or at 1 hour post dose.
| participants | Placebo | Sumatriptan 10 mg/ Naproxen 60 mg | Sumatriptan 30 mg/ Naproxen 180 mg | Sumatriptan 85 mg/ Naproxen 500 mg |
|---|---|---|---|---|
| Total Population, n=142, 96, 97, 150 | 6 | 9 | 6 | 11 |
| 12-14 years, n=70, 43, 46, 65 | 4 | 7 | 2 | 4 |
| 15-17 years, n=72, 53, 51, 85 | 2 | 2 | 4 | 7 |
Participants with sustained freedom from photophobia were those with an absence of photophobia (sensitivity to light) from 2 to 24 hours post-dose without the use of rescue medication.
| participants | Placebo | Sumatriptan 10 mg/ Naproxen 60 mg | Sumatriptan 30 mg/ Naproxen 180 mg | Sumatriptan 85 mg/ Naproxen 500 mg |
|---|---|---|---|---|
| Total Population, n=144, 96, 96, 151 | 44 | 48 | 43 | 75 |
| 12-14 years, n=71, 43, 46, 65 | 25 | 21 | 21 | 35 |
| 15-17 years, n=73, 53, 50, 86 | 19 | 27 | 22 | 40 |
Participants with sustained freedom from phonophobia were those with an absence of phonophobia (sensitivity to sound) from 2 to 24 hours post-dose without the use of rescue medication.
| participants | Placebo | Sumatriptan 10 mg/ Naproxen 60 mg | Sumatriptan 30 mg/ Naproxen 180 mg | Sumatriptan 85 mg/ Naproxen 500 mg |
|---|---|---|---|---|
| Total Population, n=144, 96, 96, 151 | 47 | 48 | 51 | 79 |
| 12-14 years, n=71, 43, 46, 65 | 27 | 24 | 31 | 36 |
| 15-17 years, n=73, 53, 50, 86 | 20 | 24 | 20 | 43 |
Participants with sustained freedom from nausea were those with an absence of nausea from 2 to 24 hours post-dose without the use of rescue medication.
| participants | Placebo | Sumatriptan 10 mg/ Naproxen 60 mg | Sumatriptan 30 mg/ Naproxen 180 mg | Sumatriptan 85 mg/ Naproxen 500 mg |
|---|---|---|---|---|
| Total Population, n=144, 95, 96, 151 | 68 | 67 | 64 | 94 |
| 12-14 years, n=71, 43, 46, 65 | 39 | 31 | 33 | 43 |
| 15-17 years, n=73, 52, 50, 86 | 29 | 36 | 31 | 51 |
Rescue medication was defined as an additional medication taken by participants for the treatment of migraine pain or associated symptoms within 24 hours of dosing with investigational product. Permitted rescue medications included oral naproxen sodium (maximum 15 mg/kg), oral over-the-counter pain reliever, and anti-emetics. This outcome measure included only participants who rescued from 2 to 24 hours post-dose, inclusive.
| participants | Placebo | Sumatriptan 10 mg/ Naproxen 60 mg | Sumatriptan 30 mg/ Naproxen 180 mg | Sumatriptan 85 mg/ Naproxen 500 mg |
|---|---|---|---|---|
| Total Population, n=145, 96, 97, 152 | 47 | 14 | 16 | 21 |
| 12-14 years, n=71, 43, 46, 65 | 21 | 5 | 6 | 10 |
| 15-17 years, n=74, 53, 51, 87 | 26 | 9 | 10 | 11 |
Rescue medication was defined as an additional medication taken by participants for the treatment of migraine pain or associated symptoms within 24 hours of dosing with double-blind treatment. In addition to participants who rescued from 2 to 24 hours post-dose, inclusive, this outcome measure also included nine protocol violators who rescued \< 2 hours post-treatment.
| participants | Placebo | Sumatriptan 10 mg/ Naproxen 60 mg | Sumatriptan 30 mg/ Naproxen 180 mg | Sumatriptan 85 mg/ Naproxen 500 mg |
|---|---|---|---|---|
| Total Population, 1 hour, n=145, 96, 96, 152 | 2 | 0 | 0 | 2 |
| Total Population, 2 hours, n=145, 96, 96, 152 | 10 | 0 | 6 | 3 |
| Total Population, 3 hours, n=145, 96, 96, 152 | 29 | 6 | 11 | 15 |
| Total Population, 4 hours, n=145, 96, 96, 152 | 34 | 6 | 13 | 16 |
| Total Population, 8 hours, n=145, 96, 96, 152 | 45 | 9 | 15 | 20 |
| Total Population, 12 hours, n=145, 96, 96, 152 | 48 | 11 | 15 | 20 |
| Total Population, 18 hours, n=145, 96, 96, 152 | 50 | 13 | 15 | 22 |
| Total Population, 24 hours, n=145, 96, 96, 152 | 52 | 14 | 17 | 23 |
| 12-14 years, 1 hour, n=71, 43, 46, 65 | 1 | 0 | 0 | 0 |
| 12-14 years, 2 hours, n=71, 43, 46, 65 | 4 | 0 | 1 | 1 |
| 12-14 years, 3 hours, n=71, 43, 46, 65 | 11 | 1 | 2 | 7 |
| 12-14 years, 4 hours, n=71, 43, 46, 65 | 14 | 1 | 4 | 8 |
| 12-14 years, 8 hours, n=71, 43, 46, 65 | 20 | 4 | 4 | 10 |
| 12-14 years, 12 hours, n=71, 43, 46, 65 | 10 | 4 | 4 | 10 |
| 12-14 years, 18 hours, n=71, 43, 46, 65 | 21 | 4 | 4 | 10 |
| 12-14 years, 24 hours, n=71, 43, 46, 65 | 22 | 5 | 6 | 10 |
| 15-17 years, 1 hour, n=74, 53, 50, 87 | 1 | 0 | 0 | 2 |
| 15-17 years, 2 hours, n=74, 53, 50, 87 | 6 | 0 | 5 | 2 |
| 15-17 years, 3 hours, n=74, 53, 50, 87 | 18 | 5 | 9 | 8 |
| 15-17 years, 4 hours, n=74, 53, 50, 87 | 20 | 5 | 9 | 8 |
| 15-17 years, 8 hours, n=74, 53, 50, 87 | 25 | 5 | 11 | 10 |
| 15-17 years, 12 hours, n=74, 53, 50, 87 | 28 | 7 | 11 | 10 |
| 15-17 years, 18 hours, n=74, 53, 50, 87 | 29 | 9 | 11 | 12 |
| 15-17 years, 24 hours, n=74, 53, 50, 87 | 30 | 9 | 11 | 13 |
The number of participants who did not have nausea at 2 hours post dose was analzyed.
| participants | Placebo | Sumatriptan 10 mg/ Naproxen 60 mg | Sumatriptan 30 mg/ Naproxen 180 mg | Sumatriptan 85 mg/ Naproxen 500 mg |
|---|---|---|---|---|
| Total Population, n=144, 95, 96, 151 | 101 | 78 | 74 | 106 |
| 12-14 years, n=71, 43, 46, 65 | 55 | 36 | 38 | 47 |
| 15-17 years, n=73, 52, 50, 86 | 46 | 42 | 36 | 59 |
The mean age of participants at baseline was calculated for all participants in the 12 to 14 year and 15 to 17 year age groups.
| Years | 12 to 14 Years Age Group | 15 to 17 Years Age Group |
|---|---|---|
| Mean Age of Participants at Baseline Categorized by Age Group | 13.1 ± 0.79 | 16.1 ± 0.84 |
The number of participants receiving double-blind treatment were reported according to age.
| Participants | Placebo | Sumatriptan 10 mg/ Naproxen 60 mg | Sumatriptan 30 mg/ Naproxen 180 mg | Sumatriptan 85 mg/ Naproxen 500 mg |
|---|---|---|---|---|
| 12-14 years | 71 | 43 | 46 | 65 |
| 15-17 years | 74 | 53 | 51 | 87 |
The gender of participants at baseline was reported for all participants in the 12 to 14 year and 15 to 17 year age groups.
| Participants | 12 to 14 Years Age Group | 15 to 17 Years Age Group |
|---|---|---|
| Female | 114 | 173 |
| Male | 111 | 92 |
The race of participants at baseline was reported for all participants in the 12 to 14 year and 15 to 17 year age groups.
| Participants | 12 to 14 Years Age Group | 15 to 17 Years Age Group |
|---|---|---|
| African American/African Heritage | 31 | 32 |
| American Indian or Alaska Native | 1 | 0 |
| Asian | 2 | 2 |
| Native Hawaiian or other Pacific Islander | 1 | 0 |
| White | 181 | 216 |
| African American/African Heritage and White | 2 | 4 |
| American Indian or Alaska Native and White | 4 | 4 |
| Asian and Native Hawaiian/other Pacific Islander | 0 | 1 |
| Asian and White | 2 | 3 |
| Native Hawaiian/ other Pacific Islander and White | 0 | 2 |
| Missing | 1 | 1 |
The mean weight of participants at baseline was calculated for all participants in the 12 to 14 year and 15 to 17 year age groups.
| Kilograms (kg) | 12 to 14 Years Age Group | 15 to 17 Years Age Group |
|---|---|---|
| Mean Weight of Participants at Baseline Categorized by Age Group | 58.7 ± 15.55 | 69.6 ± 17.78 |
The mean body mass index of participants at baseline was calculated for all participants in the 12 to 14 year and 15 to 17 year age groups. Body mass index is calculated as: weight (kilograms \[kg\]) divided by height (meters \[m\]\^2).
| Kilograms per meters squared (kg/m^2) | 12 to 14 Years Age Group | 15 to 17 Years Age Group |
|---|---|---|
| Mean Body Mass Index of Participants at Baseline Categorized by Age Group | 22.6 ± 5.06 | 24.6 ± 5.44 |
Collected over Serious adverse events (SAEs) and AEs were collected from the start of investigational product (IP) in the Run-In Phase until follow-up (up through 1 week after single dose of double-blind IP for participants who took double-blind IP, up to Week 26).. Non-serious events are listed at a 1.5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | — | 0/145 (0%) | 3/145 (2.1%) |
| Sumatriptan 10 mg/ Naproxen 60 mg | — | 0/96 (0%) | 0/96 (0%) |
| Sumatriptan 30 mg/ Naproxen 180 mg | — | 0/97 (0%) | 3/97 (3.1%) |
| Sumatriptan 85 mg/ Naproxen 500 mg | — | 0/152 (0%) | 4/152 (2.6%) |
| Single-blind Run-In Phase Placebo | — | 2/683 (0.3%) | 11/683 (1.6%) |
| Event | Placebo | Sumatriptan 10 mg/ Naproxen 60 mg | Sumatriptan 30 mg/ Naproxen 180 mg | Sumatriptan 85 mg/ Naproxen 500 mg | Single-blind Run-In Phase Placebo |
|---|---|---|---|---|---|
| Clavicle fractureInjury, poisoning and procedural complications | 0/145 | 0/96 | 0/97 | 0/152 | 1/683 |
| ConcussionInjury, poisoning and procedural complications | 0/145 | 0/96 | 0/97 | 0/152 | 1/683 |
| Jaw fractureInjury, poisoning and procedural complications | 0/145 | 0/96 | 0/97 | 0/152 | 1/683 |
| Testicular torsionReproductive system and breast disorders | 0/145 | 0/96 | 0/97 | 0/152 | 1/683 |
| Event | Placebo | Sumatriptan 10 mg/ Naproxen 60 mg | Sumatriptan 30 mg/ Naproxen 180 mg | Sumatriptan 85 mg/ Naproxen 500 mg | Single-blind Run-In Phase Placebo |
|---|---|---|---|---|---|
| NasopharyngitisInfections and infestations | 3/145 | 0/96 | 1/97 | 1/152 | 10/683 |
| Hot flushVascular disorders | 0/145 | 0/96 | 2/97 | 1/152 | 1/683 |
| Muscle tightnessMusculoskeletal and connective tissue disorders | 0/145 | 0/96 | 0/97 | 3/152 | 0/683 |
| Age, Continuous(Years) | Placebo | Sumatriptan 10 mg/ Naproxen 60 mg | Sumatriptan 30 mg/ Naproxen 180 mg | Sumatriptan 85 mg/ Naproxen 500 mg | Total |
|---|---|---|---|---|---|
| Mean | 14.7 ± 1.76 | 14.8 ± 1.81 | 14.7 ± 1.65 | 14.8 ± 1.69 | 14.7 ± 1.72 |
| Gender(Participants) | Placebo | Sumatriptan 10 mg/ Naproxen 60 mg | Sumatriptan 30 mg/ Naproxen 180 mg | Sumatriptan 85 mg/ Naproxen 500 mg | Total |
|---|---|---|---|---|---|
| Female | 85 | 52 | 56 | 94 | 287 |
| Male | 60 | 44 | 41 | 58 | 203 |
| Race/Ethnicity, Customized(participants) | Placebo | Sumatriptan 10 mg/ Naproxen 60 mg | Sumatriptan 30 mg/ Naproxen 180 mg | Sumatriptan 85 mg/ Naproxen 500 mg | Total |
|---|---|---|---|---|---|
| African American/African Heritage | 25 | 17 | 9 | 12 | 63 |
| American Indian or Alaska Native | 0 | 0 | 0 | 1 | 1 |
| Asian | 1 | 0 | 0 | 3 | 4 |
| Native Hawaiian or other Pacific Islander | 1 | 0 | 0 | 0 | 1 |
| White | 108 | 75 | 84 | 130 | 397 |
| African American/African Heritage and White | 2 | 1 | 1 | 2 | 6 |
| American Indian or Alaska Native and White | 1 | 2 | 2 | 3 | 8 |
| Asian and Native Hawaiian/other Pacific Islander | 1 | 0 | 0 | 0 | 1 |
| Asian and White | 3 | 1 | 0 | 1 | 5 |
| Native Hawaiian/ other Pacific Islander and White | 1 | 0 | 1 | 0 | 2 |
| Missing | 2 | 0 | 0 | 0 | 2 |
| Weight(Kilograms (kg)) | Placebo | Sumatriptan 10 mg/ Naproxen 60 mg | Sumatriptan 30 mg/ Naproxen 180 mg | Sumatriptan 85 mg/ Naproxen 500 mg | Total |
|---|---|---|---|---|---|
| Mean | 63.8 ± 16.67 | 64.2 ± 19.29 | 62.8 ± 14.49 | 66.8 ± 19.13 | 64.6 ± 17.63 |
| Body Mass Index(Kilograms per meters squared (kg/m^2)) | Placebo | Sumatriptan 10 mg/ Naproxen 60 mg | Sumatriptan 30 mg/ Naproxen 180 mg | Sumatriptan 85 mg/ Naproxen 500 mg | Total |
|---|---|---|---|---|---|
| Mean | 23.5 ± 5.28 | 23.3 ± 5.62 | 22.9 ± 4.53 | 24.6 ± 5.68 | 23.7 ± 5.36 |
Plan to share: Yes — Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.
The record gives a start of Dec 2008, a primary completion of May 2010 and a completion of Jun 2010. It does not say whether these dates are actual or estimated.
Results were first posted in May 2011, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Sumatriptan · Naproxen